US ophthalmic review最新文献_第9页

Keratoconus in a 4-year-old Girl with a Strong Family History of Keratoconus 圆锥角膜家族史的4岁女童一例

US ophthalmic review Pub Date : 2018-01-01 DOI: 10.17925/usor.2018.11.1.56

Mohammad M. Shehadeh, M. Akkawi, Ammar A. Aghbar

{"title":"Keratoconus in a 4-year-old Girl with a Strong Family History of Keratoconus","authors":"Mohammad M. Shehadeh, M. Akkawi, Ammar A. Aghbar","doi":"10.17925/usor.2018.11.1.56","DOIUrl":"https://doi.org/10.17925/usor.2018.11.1.56","url":null,"abstract":"Purpose: To present the diagnosis and management of the youngest-described keratoconus patient, despite the absence of any systemic or local risk factors except the presence of a strongly positive family history of keratoconus. Methods: A retrospective case report. Results: A 4-year-old female child with free past medical and ocular histories, and a strongly positive family history of keratoconus, presented with deterioration in her vision in the previous 6 months as observed by the family. Objective/subjective refraction showed high astigmatism. Corneal tomography using the Scheimpflug camera Pentacam® HR confirmed the diagnosis of keratoconus in both eyes. Conventional corneal collagen crosslinking (CXL) procedure was performed shortly with a stabilization effect observed over a 1-year follow up period. Conclusion: Keratoconus onset may occur in early childhood, especially in patients with strong family history of the disease even in the absence of systemic or ocular risk factors. So, early screening before the age of 4 years should be done for all children of a family history of keratoconus. Crosslinking may be an effective and safe procedure for very young patients diagnosed with keratoconus.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"56"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67621904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Gel Stent Implantation—Recommendations for Preoperative Assessment, Surgical Technique, and Postoperative Management 凝胶支架植入-术前评估，手术技术和术后管理的建议

US ophthalmic review Pub Date : 2018-01-01 DOI: 10.17925/usor.2018.11.1.38

Vanessa Vera, I. Ahmed, I. Stalmans, H. Reitsamer

{"title":"Gel Stent Implantation—Recommendations for Preoperative Assessment, Surgical Technique, and Postoperative Management","authors":"Vanessa Vera, I. Ahmed, I. Stalmans, H. Reitsamer","doi":"10.17925/usor.2018.11.1.38","DOIUrl":"https://doi.org/10.17925/usor.2018.11.1.38","url":null,"abstract":"T he surgical management of glaucoma offers the potential to lower intraocular pressure (IOP) independent of patients’ compliance with their medication regimen. Procedures such as trabeculectomy and tube shunt placement often yield large magnitudes of IOP reduction, but may be associated with shortand long-term complications. Microinvasive glaucoma surgery (MIGS) offers an alternative surgical approach that is inherently less invasive; however, most devices that fit in this category are associated with a lesser degree of IOP-lowering efficacy compared with traditional glaucoma surgeries. A newer MIGS device, a gel stent that facilitates drainage to the subconjunctival space, appears to offer similar IOP reduction to trabeculectomy, but with much less tissue manipulation; better predictability; and less sight-threatening complications, thus making it a potentially safer and more predictable surgical option in appropriate patients. The following proposed protocol, based on evidence-based practices and augmented where necessary by the opinions of experienced surgeons, provides guidance for the pre-, intra-, and postoperative management of patients receiving a gel stent implant. The goal of this protocol is to provide a framework for better patient selection and preparation, surgical pearls, and how best to assess and manage patients in the postoperative period.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Optical Coherence Tomography Angiography 光学相干断层血管造影术

US ophthalmic review Pub Date : 2018-01-01 DOI: 10.17925/USOR.2018.11.2.91

M. Nagpal, Gujarat India

{"title":"Optical Coherence Tomography Angiography","authors":"M. Nagpal, Gujarat India","doi":"10.17925/USOR.2018.11.2.91","DOIUrl":"https://doi.org/10.17925/USOR.2018.11.2.91","url":null,"abstract":"Optical coherence tomography angiography (OCTA) is a new revolutionary non-invasive imaging modality, built on the platform of optical coherence tomography (OCT). This technique works on the principle of ‘decorrelation’ and is still a nascent technology in its infancy with tremendous potential applicability for diagnosing retinal and choroidal vascular diseases. Its non-invasive nature, and the ability to generate images of retinal and choroidal vasculature, allows it to replace and/or supplement the current angiographic gold standards, fluorescein angiography (FA) and indocyanine green angiography (ICGA), if not in all but certainly in most retinal and choroidal pathologies. Still, there exists a major challenge in terms of its wide-scale availability, equipment and processing techniques, presence of artifacts, limitations of imaging capability, and lack of common vocabulary among retinal specialists for interpretation. In this review we intend to describe this novel technique by highlighting its key features, and comparing it with FA and ICGA. We will also discuss its applicability in various clinical scenarios such as diabetic retinopathy, age-related macular degeneration, retinal venous occlusion, choroiditis, and in routine practice. Further studies are needed to more definitively determine OCTA’s utility in the clinical setting and to establish if this technology may offer a non-invasive option of visualizing the retinal vasculature in detail.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"91"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pearls for Treating Retinoblastoma 治疗视网膜母细胞瘤的珍珠

US ophthalmic review Pub Date : 2018-01-01 DOI: 10.17925/USOR.2018.11.2.79

Sona N Shah, J. Berry

引用次数: 2

Updates and Challenges in Refractive Lens Exchange 折射透镜交换的最新进展和挑战

US ophthalmic review Pub Date : 2018-01-01 DOI: 10.17925/USOR.2018.11.1.17

D. Dhaliwal

引用次数: 0

Advances in Age-related Macular Degeneration Understanding and Therapy. 老年性黄斑变性的认识与治疗进展。

US ophthalmic review Pub Date : 2017-01-01 DOI: 10.17925/USOR.2017.10.02.119

Joan W Miller, Saghar Bagheri, Demetrios G Vavvas

引用次数: 54

Minimally Invasive Glaucoma Surgery and CyPass® Micro-Stent—A New Era in Glaucoma Surgery 微创青光眼手术和CyPass®微支架——青光眼手术的新时代

US ophthalmic review Pub Date : 2017-01-01 DOI: 10.17925/USOR.2017.10.01.39

S. Mosaed

引用次数: 3

The Value of Area Under the Curve Analysis as an Outcome Measure in the Assessment of a Continuous Microdosing Fluocinolone Acetonide Implant (ILUVIEN 曲线下面积分析在连续微剂量醋酸氟西诺酮种植体评价中的价值

US ophthalmic review Pub Date : 2017-01-01 DOI: 10.17925/USOR.2017.10.01.46

Sepehr Bahadorani, M. Singer

{"title":"The Value of Area Under the Curve Analysis as an Outcome Measure in the Assessment of a Continuous Microdosing Fluocinolone Acetonide Implant (ILUVIEN","authors":"Sepehr Bahadorani, M. Singer","doi":"10.17925/USOR.2017.10.01.46","DOIUrl":"https://doi.org/10.17925/USOR.2017.10.01.46","url":null,"abstract":"T he treatment of diabetic macular edema (DME) has become one of the most challenging management issues faced by ophthalmologists in daily practice. This is partly due to the multifactorial nature of DME, progression of the disease and the clinical capacity needed to administer intravitreal injections. In recent years, the treatment options for DME have expanded to include intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents and steroids, and most recently, the use of intravitreal implants. In determining clinically relevant endpoints for clinical studies of these treatments, it is important to consider the patient’s journey and experience with a treatment over a specific time-period rather than isolated outcomes at a pre-specified time-point. Area under the curve (AUC) is an ideal tool for data analysis particularly when it comes to sustained release therapies such as dexamethasone (Ozurdex®, Allergan Inc., California, US) and intravitreal fluocinolone acetonide implant (0.2μg/day FAc implant; Iluvien®, Alimera Sciences Inc., Georgia, US). Unlike single time-point outcomes, AUC analysis provides the average letters gained per day over the entire treatment period, providing a better measure of long-term effectiveness. A recent analysis using the AUC approach highlights the significant visual acuity benefit resulting from the 0.2μg/day fluocinolone acetonide (FAc) implant during the FAME (Fluocinolone Acetonide for Macular Edema) trials. A step-by-step instruction is included in this article that allows statistical analysis of the AUC data from both functional and anatomical outcomes, using a free software tool to further facilitate the use of this technique for future investigators.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"39 1","pages":"46"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity 抗血管内皮生长因子在早产儿视网膜病变治疗中的作用

US ophthalmic review Pub Date : 2017-01-01 DOI: 10.17925/USOR.2017.10.01.57

Christopher D Conrady, M. Hartnett

引用次数: 6

Recent Advances in the Understanding and Treatment of Glaucoma 青光眼的认识与治疗新进展

US ophthalmic review Pub Date : 2017-01-01 DOI: 10.17925/USOR.2017.10.02.89

Brandon J. Baartman, John P Berdahl

引用次数: 0